Company newsAMGN
Explain this story: Amgen Inc Stock (AMGN) Moved Up by 3.90% on Sep 22: Facts Behind the Movement
Amgen Inc. (AMGN) stock rose by 3.90% on September 22, driven by positive Phase 3 clinical trial results for dazodalibep in Sjögren's disease, which met its primary endpoint. The company's diverse late-stage pipeline, including its obesity candidate MariTide and oncology treatment IMDELLTRA, also contributed to investor confidence. Despite technical indicators showing a neutral to sell signal, analysts maintain an average price target of $389.14 with a "Hold" rating.
OtherTradingKeySector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
Amgen Inc. (AMGN) stock rose by 3.90% on September 22, driven by positive Phase 3 clinical trial results for dazodalibep in Sjögren's disease, which met its primary endpoint. The company's diverse late-stage pipeline, including its obesity candidate MariTide and oncology treatment IMDELLTRA, also contributed to investor confidence. Despite technical indicators showing a neutral to sell signal, analysts maintain an average price target of $389.14 with a "Hold" rating.
Article tone: Positive This describes the words the journalist used. It is not a prediction, and not advice.